Total Payments
$665,051
2024 Payments
$32,173
Companies
41
Transactions
415
Medicare Patients
642
Medicare Billing
$63,334
Payment Breakdown by Category
Consulting$387,915 (58.3%)
Other$217,823 (32.8%)
Travel$31,031 (4.7%)
Research$16,187 (2.4%)
Food & Beverage$6,650 (1.0%)
Education$5,444 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $387,915 | 133 | 58.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $206,942 | 83 | 31.1% |
| Travel and Lodging | $31,031 | 86 | 4.7% |
| Unspecified | $16,187 | 7 | 2.4% |
| Honoraria | $10,881 | 5 | 1.6% |
| Food and Beverage | $6,650 | 99 | 1.0% |
| Education | $5,444 | 2 | 0.8% |
Payments by Type
General
$648,864
408 transactions
Research
$16,187
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $85,410 | 48 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $82,920 | 29 | $0 (2023) |
| BeiGene USA, Inc. | $67,495 | 59 | $0 (2024) |
| Incyte Corporation | $59,021 | 43 | $0 (2023) |
| MorphoSys, US Inc. | $56,714 | 14 | $0 (2022) |
| Gilead Sciences, Inc. | $43,640 | 10 | $0 (2022) |
| Merck Sharp & Dohme LLC | $33,437 | 11 | $0 (2024) |
| ABBVIE INC. | $33,337 | 47 | $0 (2024) |
| Celgene Corporation | $19,594 | 12 | $0 (2022) |
| Adaptive Biotechnologies Corporation | $19,449 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,173 | 35 | Lilly USA, LLC ($14,740) |
| 2023 | $99,275 | 75 | Lilly USA, LLC ($66,170) |
| 2022 | $84,673 | 64 | BeiGene USA, Inc. ($25,448) |
| 2021 | $202,337 | 90 | MorphoSys, US Inc. ($48,967) |
| 2020 | $117,723 | 43 | Karyopharm Therapeutics Inc. ($73,412) |
| 2019 | $34,620 | 25 | Dr.Reddy's Laboratories,Inc. ($15,645) |
| 2018 | $59,262 | 40 | AbbVie, Inc. ($14,769) |
| 2017 | $34,989 | 43 | Bayer HealthCare Pharmaceuticals Inc. ($8,730) |
All Payment Transactions
415 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $85.97 | General |
| Category: Oncology | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | In-kind items and services | $53.00 | Research |
| Study: A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL • Category: ONCOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | In-kind items and services | $15.00 | Research |
| Study: A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL • Category: ONCOLOGY | ||||||
| 11/28/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $133.52 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $431.39 | General |
| 10/23/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Oncology | ||||||
| 10/04/2024 | CashFlow Solutions, LLC | LYMPHA PRESS OPTIMAL PLUS(US) BT (Device), PCD-51 731A (US) - White, PCD-52 737A (US) White | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Pneumatic Compressor | ||||||
| 09/10/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,175.00 | General |
| Category: Oncology | ||||||
| 07/26/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: Iron Deficiency Anemia | ||||||
| 06/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,660.00 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $97.62 | General |
| Category: ONCOLOGY | ||||||
| 04/23/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $85.05 | General |
| Category: ONCOLOGY | ||||||
| 03/19/2024 | SERVIER PHARMACEUTICALS LLC | — | Food and Beverage | In-kind items and services | $20.75 | General |
| 03/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $26.07 | General |
| Category: Oncology | ||||||
| 02/27/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 02/14/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,750.00 | General |
| Category: Oncology | ||||||
| 02/14/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | Cash or cash equivalent | $141.78 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar DRLRI With MabThera in Subjects With Previously Untreated CD20-Positive LTB Follicular Lymphoma | Dr.Reddy's Laboratories,Inc. | $15,645 | 2 |
| AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED, PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF BENDAMUSTINE COMPARED TO BENDAMUSTINE RO5072759 GA101 IN PATIENTS WITH ANTI-CD20-REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA | F. Hoffmann-La Roche AG | $458.57 | 2 |
| A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL | ABBVIE INC. | $68.00 | 2 |
| UTXTGR205 | TG Therapeutics, Inc. | $15.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 262 | 715 | $102,536 | $28,927 |
| 2022 | 6 | 194 | 603 | $69,682 | $20,030 |
| 2021 | 7 | 186 | 443 | $36,753 | $14,376 |
Total Patients
642
Total Services
1,761
Medicare Billing
$63,334
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 81 | $31,590 | $8,705 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 46 | $25,300 | $7,057 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 91 | $25,207 | $6,508 | 25.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $9,422 | $2,741 | 29.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 50 | 165 | $1,485 | $1,378 | 92.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 52 | 183 | $5,307 | $1,372 | 25.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 35 | 83 | $3,237 | $859.05 | 26.5% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 27 | 52 | $988.00 | $307.84 | 31.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 37 | 111 | $30,407 | $8,762 | 28.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 55 | $21,018 | $6,096 | 29.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $10,390 | $2,931 | 28.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 44 | 169 | $4,901 | $1,296 | 26.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 44 | 187 | $1,683 | $553.89 | 32.9% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2022 | 33 | 65 | $1,283 | $390.44 | 30.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 44 | $12,840 | $5,316 | 41.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 28 | $10,980 | $4,733 | 43.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 24 | $4,608 | $2,039 | 44.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 33 | 101 | $2,929 | $784.77 | 26.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 29 | 72 | $2,808 | $760.32 | 27.1% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2021 | 33 | 73 | $1,679 | $440.92 | 26.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 33 | 101 | $909.00 | $303.00 | 33.3% |
About Dr. Bruce Cheson, MD
Dr. Bruce Cheson, MD is a Hematology & Oncology healthcare provider based in Bethesda, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1992703862.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Cheson, MD has received a total of $665,051 in payments from pharmaceutical and medical device companies, with $32,173 received in 2024. These payments were reported across 415 transactions from 41 companies. The most common payment nature is "Consulting Fee" ($387,915).
As a Medicare-enrolled provider, Cheson has provided services to 642 Medicare beneficiaries, totaling 1,761 services with total Medicare billing of $63,334. Data is available for 3 years (2021–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Bethesda, MD
- Active Since 07/13/2005
- Last Updated 01/03/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1992703862
Products in Payments
- MONJUVI (Drug) $110,946
- XPOVIO (Drug) $82,920
- BRUKINSA (Drug) $68,670
- KEYTRUDA (Biological) $29,812
- Venclexta (Drug) $21,736
- clonoSEQ (Device) $19,449
- IMBRUVICA (Drug) $14,658
- CALQUENCE (Drug) $14,598
- JAYPIRCA (Drug) $14,397
- GAZYVA (Biological) $13,899
- Revlimid (Drug) $12,370
- Aliqopa (Drug) $10,048
- Non-Covered $8,730
- UKONIQ (Drug) $8,003
- TAZVERIK (Drug) $5,992
- COPIKTRA (Drug) $4,918
- VENCLEXTA (Drug) $4,230
- Imbruvica (Drug) $3,679
- SGN35 (Biological) $2,574
- OPDIVO (Biological) $2,326
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Bethesda
Sandra Swain, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Susan Leitman, M.d, M.D
Hematology & Oncology — Payments: $110,420
Hematology & Oncology $110,420
Chitra Rajagopal, Md, MD
Hematology & Oncology — Payments: $101,267
Hematology & Oncology $101,267
Phillip Scheinberg, M.d, M.D
Hematology & Oncology — Payments: $80,747
Hematology & Oncology $80,747
Gregory Frykman, M.d, M.D
Hematology & Oncology — Payments: $21,375
Hematology & Oncology $21,375
Dr. James Gulley, Md Phd Facp, MD PHD FACP
Hematology & Oncology — Payments: $11,595
Hematology & Oncology $11,595